Other links:
Assistant Professor of Biology, 51茶馆
Ph.D. CSIR-Indian Institute of Chemical BiologyDeblina Raychaudhuri is an Assistant Professor of Biology at 51茶馆. She completed her Integrated Bachelors and Masters degree in Biotechnology from St. Xavier鈥檚 College (University of Calcutta), Kolkata and earned her Ph.D. in Immunology from the CSIR-Indian Institute of Chemical Biology, Kolkata. Before joining Ashoka, she was a postdoctoral fellow at the MD Anderson Cancer Center, Houston, USA.
Dr. Raychaudhuri鈥檚 research focuses on human cancer immunology with a particular emphasis on understanding host-immune-tumor interactions to develop more effective and personalized cancer therapies. Her work explores how the different components of the tumor microenvironment shape tumor evolution, immune evasion and resistance to therapy. By integrating multi-omics approaches, her lab aims to uncover new mechanisms driving cancer progression and identify novel therapeutic targets. Ultimately, her research seeks to improve the efficacy of cancer immunotherapies, especially for patients in India, and to guide the development of tailored treatment strategies.
1. Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo A, Im JS, Goswami S. Histone lactylation drives CD8+ T cell metabolism and function. Nature Immunology. 2024; 25(11), 2140-2151.
2. Goswami S*, Raychaudhuri D*, Singh, P*. Natarajan SM*, Chen Y, Poon C, Hennessey M, Tannir AJ, Zhang J, Anandhan S, Kerrigan BP, Macaluso MD, He Z, Jindal S, Lang FF, Basu S, Sharma P. Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nature Cancer. 2023; 4, 1455鈥�1473.
3. Sharma P, Goswami S, Raychaudhuri D, Siddiqui B.A, Singh P, Nagarajan A, Liu J, Subudhi S.K, Poon C, Gant K.L, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023; 186:1652-1669.
4. Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nature Reviews Immunology. 2022 Jun 13;23:106鈥�120.
5. D鈥橰ozario R*, Raychaudhuri D*, Bandopadhyay P*, Sarif J*, Mehta P*, Liu CSC, Sinha BP, Roy J, Bhaduri R, Das M, et al. Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. Viruses. 2023; 15(2):549.
6. Raychaudhuri D, Bandopadhyay P, D’Rozario R, Sarif J, Ray Y, Paul SR, Singh P, Chaudhuri K, Bhaduri R, Pandey et al. Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19. Mayo Clin Proc IQ&O. 2022 Dec; 6(6):511-524.
7. Ray Y, Paul SR, Bandopadhyay P, D’Rozario R, Sarif J, Raychaudhuri D, Bhowmik D, Lahiri A, Vasudevan JS et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nature Communications. 2022 Jan 19;13(1):383.
8. Sarif J*, Raychaudhuri D*, D’Rozario R*, Bandopadhyay P*, Singh P*, Mehta P*, Hoque MA, Sinha BP, Kushwaha M, Sahni S, Devi P, Chattopadhyay P, Paul SR, Ray Y et al. Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19. Frontiers in Immunology, 2021 Oct 28;12:738093.
9. Kundu B*, Raychaudhuri D*, Mukherjee A*, Sinha BP*, Sarkar D, Bandopadhyay P, Pal S, Das N, Dey D et al. Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9. Journal of Medicinal Chemistry, 2021, 64, 13, 9279鈥�9301.
10. Mukherjee A*, Raychaudhuri D*, Sinha BP*, Kundu B, Mitra M, Paul B, Bandopadhyay P, Ganguly D, Talukdar A. A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist. Journal of Medicinal Chemistry, 2020 May 14;63(9):4776-4789.
11. Raychaudhuri D#, Duttagupta P, CSC Liu, Sarif J, Ghosh AR, Rahaman O, Ganguly D#. Role of Ca2+ in toll- like receptor 9 activation in human plasmacytoid dendritic cells. Cytokine, 2020 Jan;125(2020) :154822.
12. Raychaudhuri D, Bhattacharya R, Sinha BP, CSC Liu, Ghosh AR, Rahaman O, Bandopadhyay P, Sarif J, D鈥橰ozario R, Paul S, Das A, Sarkar DK, Chattopadhyay S, Ganguly D. Lactate Induces Pro-tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2019 Aug 7;10.1878.
